Tagged with S

Tunisia Fabrice Barbu, general manager of Servier Tunisia, discusses how Servier wants to build a strong presence in the oncology field in Tunisia and is currently investigating the possibilities of bringing its generics to the market. He also explains how local partners and highly proficient human resources have contributed to the…

Poland Marcin Czech, deputy minister and undersecretary of state at the Polish Ministry of Health, provides an in-depth perspective on Poland’s drug policy framework and the new medicines policy that aims to integrate pharmacoecomonics to ensure Poland can find an efficient balance between innovative and generic treatments for long-term stability. Furthermore,…

Canada Éric Gervais, executive vice-president of Duchesnay Inc, a privately-held, specialty Canadian pharma company focusing on women’s health, charts the company’s successful growth over the past 25 years, the innovative portfolio of in-house and in-licensed products they offer, as well as their plans for international expansion. Eric, you were Duchesnay’s first…

Canada Doug Sommerville, senior vice-president and general manager of Teva Canada, discusses Teva Canada’s enviable top five positioning within the global organization, the strength of Teva’s generics portfolio within Canada, and the critical importance of Canada possessing a local pharma manufacturing industry. Teva recently announced a new global CEO, Kåre Schultz.…

Canada Ronnie Miller, President & CEO of Roche Canada, shares the lessons learnt over his 17 years heading the affiliate, the interesting dynamics and developments within the Canadian healthcare space, Roche’s significant R&D footprint in Canada, and his focus on developing Roche Canada’s multiple sclerosis, hemophilia and neuroscience portfolios over the…

Canada Dr. Roman Szumski, vice-president of life sciences at the National Research Council (NRC), Canada’s industrial innovation and research organization, highlights the strategic and operational changes that have occurred over the past decade, NRC’s focus on promoting biologics and vaccines development within Canada’s life sciences environment, and NRC’s work in promoting…

Ukraine The Top 30 companies in Ukraine based on 2016 sales. Homegrown hero Farmak leads the way, with USD 88 million in sales for the year. French company Sanofi follows in second place.

Poland Mirosław Zieliński, president of the Polish National Forum for the Therapy of rare diseases (ORPHAN), the representative voice for 35 Polish rare disease associations, discusses the implications of the introduction of a national rare disease plan and the need to improve rare disease diagnostics. Furthermore, he highlights the importance of…

Switzerland Rocco Donnino, executive vice president of corporate development of AppRiver AG, a cybersecurity company with headquarters in Switzerland and Florida, US, discusses the strategic steps in establishing AppRiver across Europe and the services they provide, specifically the layered security approach portrayed throughout the healthcare and life science sector. Furthermore, he…

Canada Clarissa Desjardins is the founder and CEO since 2011 of Canadian biotech success story, Clementia Pharmaceuticals. She explains the different milestones of her company and her priorities moving forward. She also gives her insights on the entrepreneurship environment in Canada and advice on how to make it even more compelling…

Bulgaria Ivan Kolev, country manager at Wörwag Pharma Bulgaria, explains how has the affiliate performed over the last years as well as shares an overview about the development of diabetes and its complications, and pain management in the country. You have had two different stages at Wörwag Pharma; working in Actavis…

Tunisia Mohamed Khalil Tamim, Alcon’s head of regulatory affairs Africa manages the regulatory affairs of 47 countries in Alcon’s African cluster. He explains the necessity of creating and harmonizing medical device-specific regulatory frameworks in Africa for the benefit of patients, and documents Alcon’s strategy to navigate a price-sensitive market despite its…